Back to top
more

Xencor, Inc. (XNCR)

(Delayed Data from NSDQ)

$35.08 USD

35.08
259,567

-1.44 (-3.94%)

Updated Oct 18, 2019 03:56 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

D Value | B Growth | C Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 33.33% and 156.99%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

XNCR

Zacks Equity Research

Xencor (XNCR) Jumps: Stock Rises 7.4%

Xencor (XNCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

XNCR ESALY

Zacks Equity Research

Company News For Jun 26, 2019

Companies in the news are: ABBV, AGN, LEN, XNCR, USNA and LION

ABBV AGN LION LEN XNCR USNA HF

Zacks Equity Research

Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 220.93% and 86.41%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

XNCR

Zacks Equity Research

Nielsen (NLSN) to Report Q4 Earnings: What's in the Offing?

Partnerships and agreements are likely to drive Nielsen's (NLSN) fourth-quarter 2018 revenues. However, weakness in the Buy segment and increasing competition may impact its profits.

NLSN SQ XNCR GOGO

Zacks Equity Research

What's in Store for Booking Holdings' (BKNG) Q4 Earnings?

Booking Holdings' (BKNG) Q4 earnings are likely to reflect growth in international markets.

SQ XNCR GOGO BKNG

Zacks Equity Research

Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

XNCR

Zacks Equity Research

Xencor Sees Hammer Chart Pattern: Time to Buy?

Xencor Sees Hammer Chart Pattern: Time to Buy?

XNCR

Zacks Equity Research

Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 16.36% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

XNCR

Zacks Equity Research

Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC

Novartis AG (NVS) recently announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide from Lubris LLC.

LLY NVS GSK XNCR

Zacks Equity Research

Novartis' Tafinlar, Mekinist Get EU Approval for NSCLC

Novartis AG (NVS) recently announced that the European Commission has approved Tafinlar in combination with Mekinist for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC).

LLY NVS GSK XNCR

Zacks Equity Research

Increased Earnings Estimates Seen for Xencor (XNCR): Can It Move Higher?

Xencor (XNCR) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.

XNCR

Zacks Equity Research

Novartis' Acute Heart Failure Drug Fails in Late-Stage Study

Novartis AG (NVS) recently suffered a setback on the announcement of disappointing data from a phase III study, RELAX-AHF-2, on pipeline candidate serelaxin (RLX030).

LLY NVS GSK XNCR

Zacks Equity Research

Novartis (NVS) Announces Positive Data on Heart Failure Drug

Novartis AG (NVS) recently announced results of a new post-hoc analysis from the PARADIGM-HF study on heart failure drug Entresto.

LLY NVS GSK XNCR

Zacks Equity Research

Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy

Novartis AG (NVS) announced that the FDA has approved Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, HR+/HER2- advanced or metastatic breast cancer.

NVS GSK XOMA XNCR